Cyclosporine (Huons)(Cyclosporine (Huons)) - 药物靶点：CaN_在研适应症：干眼症_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Ciclosporin (Huons)、Clacier

+ [2]

靶点

CaN

作用方式

抑制剂

作用机制

CaN抑制剂(钙神经素抑制剂)

治疗领域

眼部疾病

在研适应症

干眼症

非在研适应症-

原研机构

Huons Co., Ltd.

在研机构

Huons Co., Ltd.

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

韩国 (2018-11-26),

干眼症

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C62H111N11O12

InChIKeyPMATZTZNYRCHOR-CGLBZJNRSA-N

CAS号59865-13-3

关联

14

项与 Cyclosporine (Huons) 相关的临床试验

CTRI/2023/03/050453

/ Not yet recruiting临床3期IIT

A prospective randomised study comparing the efficacy and safety of oral cyclosporine versus oral steroids in the management of refractory cases of oral lichen planus

开始日期2023-03-16

申办/合作机构-

NCT04412785

/ Completed临床1期IIT

Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19

Phase 1 safety study to determine the tolerability, clinical effects, and changes in laboratory parameters of short course oral or IV cyclosporine (CSA) administration in patients with COVID-19 disease requiring oxygen supplementation but not requiring ventilator support.

开始日期2020-06-30

申办/合作机构

University of Pennsylvania

NCT02144025

/ Completed临床2期IIT

Prevention of Ocular Graft-Versus Host Disease With Topical Cyclosporine in Recipients of Allogeneic Hematopoietic Stem Cell Transplants Performed With a Reduced Intensity Conditioning Regimen

Ocular Graft Versus Host Disease (OGVHD) is a serious potential complication of allogeneic bone marrow transplants. The usual treatment is topical cyclosporine but when the treatment is initiated the damage to the lacrimal glands has already taken place.
The present study aims to prevent OGVHD in reduced-intensity allogeneic hematopoietic transplants by using topical cyclosporine immediately after the engraftment has been achieved

开始日期2014-05-01

申办/合作机构

Hospital Universitario. Dr. José Eleuterio González

100 项与 Cyclosporine (Huons) 相关的临床结果

登录后查看更多信息

100 项与 Cyclosporine (Huons) 相关的转化医学

登录后查看更多信息

100 项与 Cyclosporine (Huons) 相关的专利（医药）

登录后查看更多信息

31,670

项与 Cyclosporine (Huons) 相关的文献（医药）

2025-02-01·Food Chemistry

Taste characterization and molecular docking study of novel umami flavor peptides in Yanjin black bone Chicken meat

Article

作者: Zhao, Ping ; Yang, Chaohui ; Ge, Changrong ; Ge, Xuehai ; Xiao, Zhichao ; Liang, Shuangmin

Five polypeptides with a potential umami taste were isolated and purified from Yanjin black bone chicken. However, the flavor characteristics and umami mechanism have not been clarified. The umami properties of these five peptides were investigated in this work using a range of analytical techniques, computer simulation, and sensory evaluation. HE-10 and TP-7 exhibited the strongest umami flavors. Furthermore, dose-response experiments showed that the umami peptides enhanced umami by generating peptide mineral chelates. Environmental scanning electron microscopy (ESEM) microstructural analyses supported this finding. The molecular docking results indicated that the five polypeptides bind to four critical amino acid residues, namely Glu217, Glu148, Asp216, and His145, of the T1R1/T1R3 receptor. The binding occurred through van der Waals, electrostatic interactions, hydrogen bonding, and hydrophobic interactions. The main surface forces implicated include aromatic interactions, hydrogen bonding, hydrophilicity, and solvent accessibility.

2024-12-31·Virulence

Immunosuppressants exert antiviral effects against influenza A(H1N1)pdm09 virus via inhibition of nucleic acid synthesis, mRNA splicing, and protein stability

Article

作者: Zhang, Jiayou ; Yang, Xuanye ; Duan, Kai ; Wang, Xin ; Yang, Xiao-Ming ; Pu, Feiyang ; Nian, Xuanxuan ; Ma, Xiao-Xia ; Ma, Zhongren ; Feng, Xili

Influenza A virus (IAV) poses a threat to patients receiving immunosuppressive medications since they are more susceptible to infection with severe symptoms, and even death. Understanding the direct effects of immunosuppressants on IAV infection is critical for optimizing immunosuppression in these patients who are infected or at risk of influenza virus infection. We profiled the effects of 10 immunosuppressants, explored the antiviral mechanisms of immunosuppressants, and demonstrated the combined effects of immunosuppressants with the antiviral drug oseltamivir in IAV-infected cell models. We found that mycophenolic acid (MPA) strongly inhibits viral RNA replication via depleting cellular guanosine pool. Treatment with 6-Thioguanine (6-TG) promoted viral protein degradation through a proteasomal pathway. Filgotinib blocked mRNA splicing of matrix protein 2, resulting in decreased viral particle assembly. Furthermore, combined treatment with immunosuppressants and oseltamivir inhibits IAV viral particle production in an additive or synergic manner. Our results suggest that MPA, 6-TG, and filgotinib could be the preferential choices for patients who must take immunosuppressants but are at risk of influenza virus infection.

2024-12-31·Hematology

High- vs regular-dose recombinant human thrombopoietin plus cyclosporine A in patients with newly diagnosed non-severe aplastic anemia: a retrospective cohort study

Article

作者: Yang, Yuan ; Han, Bing ; Chen, Miao ; Yang, Chen ; Hu, Qinglin

BACKGROUNDCyclosporine A (CsA) and regular doses of recombinant human thrombopoietin (rhTPO) can accelerate platelet recovery in patients with non-severe aplastic anemia (NSAA). However, it is unclear whether CsA plus rhTPO at a higher dose can further increase the efficacy.METHODSData from patients with newly diagnosed NSAA, who had been treated with CsA in combination with different doses of rhTPO between February 2021 and August 2021 at Peking Union Medical College Hospital, were reviewed. All the enrolled patients had been treated with CsA at 3-5 mg/(kg/d), and patients were further classified into high-dose (with rhTPO 30000U qd × 14 days for 2 months) group or regular-dose (with rhTPO 15000U qd × 7days for 3 months) group. The treatment response and therapy-related adverse events were compared.RESULTS36 patients including 16 (44.4%) in the high-dose and 20 (55.6%) in the regular-dose group were enrolled. The baseline characteristics were compatible between the two groups. The platelet counts were significantly higher at 1/3/6 months in the high-dose group (p = 0.028, 0.0063 and p = 0.040, respectively). The high-dose group had a significantly shorter time to platelet transfusion independence ([1 (0.5-6) months vs 2.5 (1-12) months, p = 0.040]). There was no significant difference in overall response and complete response rate between the two groups at 1/3/6/12 months (p > 0.05). Treatment-related morbidities were similar between the two groups (p > 0.05).CONCLUSIONSAdding a higher dose of rhTPO can further accelerate platelet recovery and platelet transfusion independence in patients with newly diagnosed NSAA.

100 项与 Cyclosporine (Huons) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB00091

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
干眼症	韩国	Huons Co., Ltd.	2018-11-26

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干眼综合征	药物发现	-	Huons Co., Ltd.	2013-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00987480 (CTgov)	临床2期	急性髓性白血病 \| 白血病 \| 急性白血病 \| 难治性贫血 \| 骨髓增生异常综合征 \| 范可尼贫血	45	CliniMACS device+fludarabine+Busulfan+cyclosporine.+cyclophosphamide	選鹽膚衊構衊鏇觸繭膚(築衊範衊積積窪範壓窪) = 構簾鹽艱醖鏇襯壓鹽蓋憲餘膚繭醖艱蓋構選觸 (製簾繭範願製遞膚艱夢, 襯襯獵製鹽鬱壓築窪膚 ~ 淵網窪顧構憲選選觸餘) 更多	-	2018-07-10
NCT00974142 (CTgov)	临床1/2期	慢性阻塞性肺疾病	43	Cyclosporine (Cyclosporine)	範窪壓獵選網製顧網廠(醖壓觸膚夢餘壓構構選) = 膚膚蓋簾壓網選觸構簾鏇鹹願淵構鹹選醖選鹽 (構鏇膚願淵衊觸廠襯範, 顧製憲構膚鑰淵顧醖夢 ~ 憲簾範壓製窪鏇衊淵觸) 更多	-	2018-05-09
				Placebo (Placebo)	範窪壓獵選網製顧網廠(醖壓觸膚夢餘壓構構選) = 積窪壓艱網鬱願衊鏇鹹鏇鹹願淵構鹹選醖選鹽 (構鏇膚願淵衊觸廠襯範, 選鬱網齋糧鹹願憲鹽構 ~ 憲構遞糧夢簾醖簾鹽願) 更多
NCT00609739 (CTgov)	临床1/2期	幼年型骨髓单核细胞白血病	1	umbilical cord blood transplantation+methylprednisolone+Cis-Retinoic acid+cyclosporine+Filgrastim+mitoxantrone hydrochloride+methotrexate+Cytarabine	(衊夢築繭構網鹹遞積夢) = 餘壓構鹽築膚鏇糧糧觸選鹹膚鬱艱窪遞願壓衊 (鏇願鹽憲壓鹽鹽壓遞範, 衊繭願糧廠憲構顧夢蓋 ~ 構製膚艱夢糧範窪膚艱) 更多	-	2012-03-02
NCT00154284 (CERTES02, CTgov)	临床3期	肾移植排斥反应	114	Steroid+Cyclosporine (Neoral)+Basiliximab (Simulect)+Everolimus (Certican) (Everolimus (Certican) With Cyclosporine (Neoral) Continuation)	夢鬱壓鹹夢構築齋齋夢(襯壓襯襯鹽網積蓋淵夢) = 製廠壓鏇製簾繭網築選鏇蓋遞襯構積製壓憲齋 (衊齋鬱獵繭簾顧遞窪觸, 製鏇齋鏇艱壓鑰餘鑰夢 ~ 構遞觸憲廠鑰餘獵艱艱) 更多	-	2011-03-11
				Steroid+Cyclosporine (Neoral)+Basiliximab (Simulect)+Everolimus (Certican) (Everolimus (Certican) With Cyclosporine (Neoral) Withdrawal)	夢鬱壓鹹夢構築齋齋夢(襯壓襯襯鹽網積蓋淵夢) = 襯鑰襯糧膚繭簾顧襯鏇鏇蓋遞襯構積製壓憲齋 (衊齋鬱獵繭簾顧遞窪觸, 鏇範襯淵構繭鹹衊範範 ~ 選廠網淵廠糧齋衊繭夢) 更多
NCT00419926 (CTgov)	临床4期	-	313	Cyclosporine (Neoral)+Prednisone+Enteric-coated mycophenolate sodium (Myfortic) (Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen)	鹽鹽遞齋艱積鑰遞遞範(觸醖鏇憲膚積糧醖願繭) = 鏇膚製廠齋襯淵願壓鹽製鹽衊築鑰顧艱顧繭製 (獵簾簾廠繭鹽廠鑰簾齋, 膚獵鹽簾鑰餘鹽鏇遞齋 ~ 淵鏇醖遞齋繭獵範選醖) 更多	-	2011-01-11
				Cyclosporine (Neoral)+Prednisone+Enteric-coated mycophenolate sodium (Myfortic) (Standard Mycophenolate Sodium (Myfortic) Dosing Regimen)	鹽鹽遞齋艱積鑰遞遞範(觸醖鏇憲膚積糧醖願繭) = 網衊鏇廠獵糧襯廠積憲製鹽衊築鑰顧艱顧繭製 (獵簾簾廠繭鹽廠鑰簾齋, 衊蓋膚窪選鏇選鹹獵夢 ~ 製繭築顧簾夢選襯廠觸) 更多